Investor Presentaiton

Anticipated Achieved . Achieved and Anticipated Milestones from 2021 to Early 2022 6 6 9 8 Multiple Capacity Multiple Commercial portfolio TYVYTⓇ BYVASDAⓇ SULINNOⓇ HALPRYZAⓇ Pemazyre® (Taiwan market) Potential NDA approvals TYVYTⓇ 1L nsqNSCLC Potential NDA acceptance TYVYTⓇ 1L nsqNSCLC, US BLA IBI-375 (FGFR) 1L sq NSCLC 1L HCC BYVASDAⓇ 1L HCC 2L MCCA, mainland China IBI-375 (FGFR) 2L mCCA, Hong Kong BYVASDAⓇ Indonesia NDA Pivotal trial data release / readout TYVYTⓇ 2L sqNSCLC 1L ESCC (met endpoint) 1L GC (met endpoint) IBI-306 (PCSK9) HeFH (met endpoint) Other clinical data readout Capacity expansion IBI-362 (OXM3) Obesity IBI-110 (LAG-3) Phase 1 dosage escalation TYVYTⓇ BYVASDAⓇ SULINNOⓇ • HALPRYZA® • Pemazyre® (Taiwan market) . IBI-348 (BCR-ABL/KIT) TYVYTⓇ 2L sq NSCLC IBI-348 (BCR-ABL/KIT) Drug-resistant and T3151-mutation CML Prioritized clinical assets Phase 3 or pivotal phase 2 - IBI-310 (CTLA-4) IBI-306 (PCSK9) IBI-375 (FGFR) - IBI-376 (PI3KS) IBI-344 (ROS1/NTRK) - IBI-326 (BCMA CAR-T) Phase 2/ Phase 1b - IBI-188 (CD47) IBI-110 (LAG-3) TYVYTⓇ TYVYTⓇ IBI-362 (OXM3) Complete construction of 36,000L production lines - IBI-362 (OXM3) - 1L ESCC 2L EGFR+ NSCLC Diabetes IBI-302 (VEGF/compliment) - 1L GC • IBI-375 (FGFR) • IBI-310 (CTLA-4) 2L EGFR+NSCLC 2L MCCA • IBI-376 (PI3K8) IBI-315 (PD-1/Her2) Increase total production capacity from 24,000L to 60,000L Phase 1 ongoing IBI-322 (PD-L1/CD47) IBI-376 (PI3K8) - IBI-939 (TIGIT) r/r FL - r/r FL IBI-326 (BCMA CAR-T) • IBI-344 (ROS1/NTRK) IBI-302 (VEGF/compliment) IBI-188 (CD-47) IBI323 (LAG-3/PD-L1) - IBI321 (TIGIT/PD-1) - r/r MM NSCLC IBI319 (PD-1/4-1BB) IBI-315 (PD-1/Her2) By end of 2021 to early 2022, we expect to have six commercial products and diverse clinical stage assets that drive long-term Innovent upside potentials. Confidential Copyright©2021 Innovent Biologics 13

View entire presentation